Literature DB >> 29880414

Surgically Treated Unsuspected N2-Positive NSCLC: Role of Extent and Location of Lymph Node Metastasis.

Saana Andersson1, Ilkka Ilonen1, Tommi Järvinen1, Ville Rauma1, Jari Räsänen2, Jarmo Salo1.   

Abstract

BACKGROUND: The role of surgery in the treatment of non-small-cell lung cancer that has spread to ipsilateral mediastinal or hilar lymph nodes (LNs) is controversial. We examined whether the location of LNs positive for non-small-cell lung cancer in mediastinum or hilum influences the survival of these patients. PATIENTS AND METHODS: We reviewed data from 881 patients and analyzed those with unsuspected N2 disease or hilar (station 10) LNs. The patients were stratified into the following groups: group A, positive hilar Naruke 10; group B, superior mediastinal and aortic nodes (Naruke 1, 2, 3, 4, 5, and 6); group C, inferior mediastinal nodes (Naruke 7, 8, and 9), and multilevel group D (2 or more positive N2 levels).
RESULTS: A total of 69 pN2 and 19 pN1 patients were included. Progression-free survival (PFS) was statistically significant better in group B versus group C (P = .044) and group B versus group D (P = .0086). The overall survival (OS) of group A did not differ from that of group C. A statistically significant better OS was found between groups B and D (P = .051).
CONCLUSION: Inferior positive mediastinal N2 node patients seem to have an OS and PFS as poor as multilevel N2 disease patients. The OS and PFS of patients with positive hilar disease are similar to those in the inferior mediastinal positive N2 group. Superior positive mediastinal N2 node patients have better OS and PFS than the inferior mediastinal positive N2 group.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  NSCLC; Positive mediastinal lymph node; Surgery

Mesh:

Year:  2018        PMID: 29880414     DOI: 10.1016/j.cllc.2018.04.011

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  3 in total

1.  Oncological outcomes of unsuspected pN2 in patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Michiel A IJsseldijk; Richard P G Ten Broek; Bastiaan Wiering; Edo Hekma; Marnix A J de Roos
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

2.  Long-term clinical outcomes and prognostic factors of upfront surgery as a first-line therapy in biopsy-proven clinical N2 non-small cell lung cancer.

Authors:  Luca Bertolaccini; Elena Prisciandaro; Juliana Guarize; Lara Girelli; Giulia Sedda; Niccolò Filippi; Filippo de Marinis; Lorenzo Spaggiari
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

3.  Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Awrad Nasralla; Jeremy Lee; Jerry Dang; Simon Turner
Journal:  J Cardiothorac Surg       Date:  2020-10-15       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.